

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

1  
2  
3  
4  
5  
6  
**Viral cultures for COVID-19 infectivity assessment – a systematic review**

Jefferson T<sup>1</sup>; Spencer EA<sup>1</sup>; Brassey J<sup>2</sup>; Heneghan C<sup>1</sup>.

7  
8  
9  
**Affiliations**

1. Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Oxford, OX2 6GG
2. Trip Database Ltd

10  
11  
12  
13  
14  
**Keywords:** Covid-19; mode of transmission, viral culture; symptom onset to test date; polymerase chain reaction; SARS-CoV-2; infectivity.

15  
16  
17  
18  
19  
Joint corresponding authors:

Jefferson ([tom-jefferson@conted.ox.ac.uk](mailto:tom-jefferson@conted.ox.ac.uk))

Heneghan ([Carl.heneghan@phc.ox.ac.uk](mailto:Carl.heneghan@phc.ox.ac.uk))

20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
**Summary**

We report the results of a review of the evidence from studies comparing SARS-CoV-2 culture with reverse transcriptase polymerase chain reaction (rt-PCR), as viral culture represents the best indicator of current infection and infectiousness of the isolate.

We identified fourteen studies succeeding in culturing or observing tissue invasion by SARS-CoV in sputum, naso or oropharyngeal, urine, stool and environmental samples from patients diagnosed with Covid-19.

The data are suggestive of a relation between the time from collection of a specimen to test, copy threshold, and symptom severity, but the quality of the studies was moderate with lack of standardised reporting and lack of testing of PCR against viral culture or infectivity in animals. This limits our current ability to quantify the relationship between viral load, cycle threshold and viable virus detection and ultimately the usefulness of PCR use for assessing infectiousness of patients.

Prospective routine testing of reference and culture specimens are necessary for each country involved in the pandemic to establish the usefulness and reliability of PCR for Covid-19 and its relation to patients' factors such as date of onset of symptoms and copy threshold, in order to help predict infectivity.

## 34 Introduction

35 The ability to make decisions on the prevention and management of Covid-19 infections rests on our  
36 capacity to identify those who are infected. In the absence of predictive clinical signs or symptoms<sup>1</sup>, the most  
37 widely used means of detection is molecular testing using Reverse Transcriptase quantitative Polymerase  
38 Chain Reaction (RT-qPCR)<sup>2,3</sup>.

39 The test amplifies genomic sequences identified in samples. As it is capable of generating results from small  
40 samples - it is very sensitive. Amplification of genomic sequence is measured in cycle thresholds (Ct). There  
41 appears to be a correlation between Ct values from respiratory samples, symptom onset to test (STT) date  
42 and positive viral culture. The lower the Ct value (as a proxy for total viral load) and the shorter the STT, the  
43 higher the infectivity potential<sup>4</sup>.

44 Whether probing for sequences or whole genomes<sup>5</sup>, in the diagnosis of Covid-19 a positive RT-qPCR cannot  
45 tell you whether the person is infectious or when the infection began, nor the provenance of the genetic  
46 material. Very early in the outbreak it was recognised that cycle threshold values are a quantitative measure  
47 of viral load, but correlation with clinical progress and transmissibility was not yet known<sup>6</sup>. A positive result  
48 indicates that a person has come into contact with the genomic sequence at some time in the past. However,  
49 presence of viral genome on its own is not sufficient proof of infectivity and caution is needed when  
50 evaluating the infectivity of specimens simply based on the detection of viral nucleic acids<sup>5</sup>. In addition, viral  
51 genomic material can be still be present weeks after infectious viral clearance.<sup>7</sup> Like all tests, RT-qPCR  
52 requires validation against a gold standard. In this case isolation of a whole virion (as opposed to fragments)  
53 and proof that the isolate is capable of replicating its progeny in culture cells is the closest we are going to  
54 get to a gold standard.<sup>8</sup>

55 Our [Open Evidence Review](#) of transmission modalities of SARS CoV-2 identified a low number of studies  
56 which have attempted viral culture. There are objective difficulties in doing such cultures such as the  
57 requirement for a level III laboratory, time and the quality of the specimens as well as financial availability of  
58 reagents and culture media to rule out the presence of other pathogens.

59 As viral culture represents the best indicator of infection and infectiousness, we set out to review the  
60 evidence on viral culture compared to PCR, and report the results of those studies attempting viral culture  
61 regardless of source (specimen type) of the sample tested.

## 62 Methods

63 We conducted an initial search using LitCovid, medRxiv, Google Scholar and Google for Covid-19 using the  
64 terms 'viral culture' or 'viral replication' and associated synonyms. Search last updated 30<sup>th</sup> July 2020.  
65 Results were reviewed for relevance and searches were stopped when no new relevant articles were  
66 apparent. For articles that looked particularly relevant citation matching was undertaken and relevant results  
67 were identified.

68 We included studies reporting attempts to culture SARS-CoV-2 and those which also estimated the  
69 infectiousness of the isolates. One reviewer extracted data for each study and a second review checked and  
70 edited the extraction. We tabulated the data and summarised data narratively by mode of sample: fecal,  
71 respiratory, environment or mixed.

72 Where necessary we wrote to corresponding authors of the included or background papers for additional  
73 information. We assessed quality using a modified QUADAS 2 risk of bias tool. We simplified the tool as the  
74 included studies were not designed as primary diagnostic accuracy studies.<sup>9</sup>

75 This review is part of an [Open Evidence Review](#) on Transmission Dynamics of COVID-19. Summaries of the  
76 included studies and the protocol (v1) are available at: [https://www.cebm.net/evidence-  
77 synthesis/transmission-dynamics-of-covid-19/](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/). Searches are updated every 2 weeks.

## 78 Results

79 We identified 114 articles of possible interest and after screening full texts included 14 (see PRISMA<sup>10</sup> flow  
80 chart - Figure 1). The salient characteristics of each study are shown in Table 1.

81 All 14 studies were case series of **moderate quality** (Table 2. Quality of included studies). We could not  
82 identify a protocol for any of the studies. All the included studies had been either published or were available

85 as preprints; all had been made public in 2020. We received four responses from authors regarding clarifying  
86 information (see Acknowledgments).

87

### 88 **Studies using fecal samples**

89 Five studies used fecal samples which were positive for SARS-CoV-2 based on RT-PCR result<sup>11-15</sup> and  
90 reported achieving viral isolation, and one laboratory study<sup>16</sup> found that SARS-CoV-2 infected human small  
91 intestinal organoids. A further study visually identified virions in colon tissue<sup>17</sup>

92

### 93 **Studies using respiratory samples**

94 Three studies on respiratory samples report achieving viral isolation. One study assessed 90  
95 nasopharyngeal samples and cultured 26 of the samples, and positive cultures were only observed up to day  
96 eight post symptom onset; <sup>4</sup> another study obtained 31 cultures from 46 nasopharyngeal and oropharyngeal  
97 samples; <sup>18</sup> while 183 nasopharyngeal and sputum samples produced 124 cases in which a cytopathic effect  
98 was observed although the denominator of samples taken was unclear <sup>19</sup>.

99

### 100 **Studies using environmental samples**

101 Two possible positive cultures were obtained from 95 environmental samples in one study that assessed the  
102 aerosol and surface transmission potential of SARS-CoV-2 <sup>20</sup>.

103

### 104 **Mixed sources**

105 Five studies reported viral culture from mixed sources. Using 60 samples from 50 cases of Covid-19, viral  
106 culture was achieved from 12 oropharyngeal, nine nasopharyngeal and two sputum samples<sup>5</sup>. Jeong et al <sup>11</sup>  
107 who reported isolation live virus from a stool sample also reported that from of an unreported number of  
108 nasopharyngeal, oropharyngeal, saliva, sputum and stool samples, one viral culture was achieved: ferrets  
109 inoculated with these samples became infected; SARS-CoV-2 was isolated from the nasal washes of the two  
110 urine-treated ferrets and one stool-treated ferret<sup>11</sup>. An unreported number of samples from saliva, nasal  
111 swabs, urine, blood and stool collected from nine Covid-19 patients produced positive cultures and a  
112 possible specimen stool culture<sup>21</sup>. One study showed that from nine nasopharyngeal, oropharyngeal, stool,  
113 serum and urine samples, all nine were culturable, including two from non-hospitalised Covid-19 patients<sup>22</sup>.  
114 Yao and colleagues cultured viable viral isolates from seven sputum samples, three stool samples and one  
115 nasopharyngeal sample of 11 patient aged 4 months to 71 years, indicating that the SARS-CoV-2 is capable  
116 of replicating in stool samples as well as sputum and the nasopharynx. <sup>23</sup> All samples had been taken within  
117 5 days of symptom onset. The authors also report a relationship between viral load (copy thresholds) and  
118 cytopathic effect observed in infected culture cells <sup>24</sup>

119

### 120 **The relationship between RT-PCR results and viral culture of SARS-CoV-2**

121 It is not possible due to the reporting within the studies to currently make a quantitative assessment of the  
122 association between RT-PCR results and the success rate of viral culture within these studies. These studies  
123 were not adequately sized nor performed in a sufficiently standardised manner and may be subject to  
124 reporting bias.

125

### 126 **Discussion**

127 This review shows that a number of studies have attempted and successfully achieved culture of SARS-  
128 CoV-2 in the laboratory, using a range of respiratory, fecal or environmentally collected samples. The rate of  
129 success is difficult to assess from available studies, and additional studies that we are unaware of may have  
130 been performed with no viral culture achieved. There may be a positive relationship between lower cycle  
131 count threshold and viral culturability, but more studies with standardised methods are needed to establish  
132 the magnitude and reliability of this association.

133

134 The purpose of viral testing is to assess the relation of the micro-organism and hazard to humans, i.e. its  
135 clinical impact on the individual providing the sample for primary care and the of risk of transmission to  
136 others for public health. PCR on its own is unable to provide such answers. When interpreting the results of

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

137 rt-PCR it is important to take into consideration the clinical picture, the cycle threshold value and the number  
138 of days from symptom onset to test (STT)<sup>25</sup>. Several of our included studies assessed the relationship of  
139 these variables and there appears to be a time window during which shedding is at its highest with low copy  
140 threshold and higher possibility of culturing a live virus. We propose that further work should be done on this  
141 with the aim of constructing a calibrating algorithm for PCR which are likely to detect infectious patients. PCR  
142 should be continuously calibrated against a reference culture in Vero cells in which cytopathic effect has  
143 been observed<sup>4</sup>. Confirmation of visual identification using methods such as an immunofluorescence assay  
144 may also be relevant for some virus types<sup>8</sup>

145  
146 We are unsure whether SARS CoV-2 methods of cell culture have been standardised. Systems can vary  
147 depending upon the selection of the cell lines; the collection, transport, and handling of and the maintenance  
148 of viable and healthy inoculated cells<sup>26</sup>. We therefore recommend that standard methods for culture should  
149 be urgently developed. If identification of viral infectivity relies on visual inspection of cytopathogenic effect,  
150 then a reference culture of cells must also be developed to test recognition against infected cells. Viral  
151 culture may not be appropriate for routine daily results, but specialized laboratories should rely on their own  
152 ability to use viruses as controls, perform complete investigations when needed, and store representative  
153 clinical strains whenever possible<sup>26</sup>. In the absence of a culture, ferret inoculation of specimen washings and  
154 antibody titres could also be used. It may be impossible to produce a universal Cycle threshold value as this  
155 may change with circumstances (e.g. hospital, community, cluster and symptom level) and the current  
156 evidence base is thin.

157  
158 We suggest the WHO produce a protocol to standardise the use and interpretation of PCR and routine use  
159 of culture or animal model to continuously calibrate PCR testing, coordinated by designated [Biosafety Level](#)  
160 [III laboratory](#) facilities with inward directional airflow<sup>27</sup>.

161 The results of our review are similar to those of the living review by Cevick and colleagues<sup>28</sup>. Although the  
162 inclusion criteria are narrower than ours, the authors reviewed 79 studies on the dynamics, load and  
163 shedding for SARS CoV-1, MERS and SARS CoV-2 from symptoms onset. They conclude that although  
164 SARS-CoV-2 RNA shedding in respiratory (up to 83 days) and stool (35 days) can be prolonged, duration of  
165 viable virus is relatively short-lived (up to a maximum of 8 days from symptoms onset). Results that are  
166 consistent with Bullard et al who found no growth in samples with a cycle threshold greater than 24 or when  
167 symptom onset was greater than 8 days. Thus, blanket detection of viral RNA cannot be used to infer  
168 infectiousness. Length of excretion is also linked to age, male gender and use of steroids and possible  
169 severity of illness. Of note, live virus excretion peaked later in SARS CoV-1 and MERS<sup>28</sup>

170  
171 The limits of our review are the low number of studies of relatively poor quality with lack of standardised  
172 reporting and lack of gold testing for each country involved in the pandemic. This limits our ability to quantify  
173 the relationship between viral load, cycle threshold and viable virus detection. We plan to keep updating this  
174 review with emerging evidence.

## 175 176 **Conclusion**

177  
178 The current data are suggestive of a relation between the time from collection of a specimen to test, copy  
179 threshold, and symptom severity, but the quality of the studies limits firm conclusions to be drawn. We  
180 recommend that a uniform international standard for reporting of comparative SARS-CoV-2 culture with  
181 index test studies be produced. Particular attention should be paid to the relationship between the results of  
182 testing, clinical conditions and the characteristics of the source patients, description of flow of specimens and  
183 testing methods. Defining cut off levels predictive of infectivity should be feasible and necessary for  
184 diagnosing viral respiratory infections using molecular tests<sup>29</sup>.

## 185 186 187 **Acknowledgments**

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

188 Drs Susan Amirian, Siyuan Ding, Long Rong and Sravanthi Parasato provided additional information for this  
189 brief. Dr Maryanne DeMasi helped with reference identification.

190  
191 **Funding**

192 The reviews was partly funded by NIHR Evidence Synthesis Working Group project 380 and supported by  
193 the Maria and David Willets foundation.

194  
195 **Disclaimer:** The article has not been peer-reviewed. The views expressed in this commentary represent the  
196 views of the authors and not necessarily those of the host institution, the NHS, the NIHR, or the Department  
197 of Health and Social Care. The views are not a substitute for professional medical advice. It will be regularly  
198 updated see the evidence explorer at [https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/)  
199 [covid-19/](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/) for regular updates to the evidence summaries and briefs.

200  
201 **Data Availability**

202 All data included in the review are from publications or preprints. All extractions sheets with direct links to the  
203 source paper are available from [https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/)  
204 [19/](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/)

205  
206 **Authors:**

207 Tom Jefferson is a senior associate tutor and honorary research fellow, Centre for Evidence-Based  
208 Medicine, University of Oxford. Disclosure statement is here

209  
210 Elizabeth Spencer is Epidemiology and Evidence Synthesis Researcher at the Centre for Evidence-Based  
211 Medicine. (Bio and disclosure statement here)

212  
213 Jon Brassey is the Director of Trip Database Ltd, Lead for Knowledge Mobilisation at Public Health Wales  
214 (NHS) and an Associate Editor at the BMJ Evidence-Based Medicine.

215  
216 Carl Heneghan is Professor of Evidence-Based Medicine, Director of the Centre for Evidence-Based  
217 Medicine and Director of Studies for the Evidence-Based Health Care Programme. (Full bio and disclosure  
statement here)

218 This work is licensed under a [Creative Commons Attribution-NonCommercial 4.0 International License](#).

219  
220  
221 **References**

- 222 1. Wynants L, Van Calster B, Collins GS, et al. Prediction models for diagnosis and prognosis of covid-19:  
223 systematic review and critical appraisal. *BMJ* 2020;369:m1328. doi: 10.1136/bmj.m1328
- 224 2. Transmission of SARS-CoV-2: implications for infection prevention precautions. Scientific brief.  
225 . 2020
- 226 3. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) 16-24 February 2020.  
227 2020
- 228 4. Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. LID -  
229 10.1093/cid/ciaa638 [doi] LID - ciaa638. (1537-6591 (Electronic))
- 230 5. Huang C-G, Lee K-M, Hsiao M-J, et al. Culture-Based Virus Isolation To Evaluate Potential Infectivity of  
231 Clinical Specimens Tested for COVID-19. *J Clin Microbiol* 2020;58(8):e01068-20. doi:  
232 10.1128/jcm.01068-20
- 233 6. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected  
234 With SARS-CoV-2 in Singapore. (1538-3598 (Electronic))
- 235 7. Atkinson B, Petersen E. SARS-CoV-2 shedding and infectivity. *The Lancet* 2020;395(10233):1339-40. doi:  
236 10.1016/S0140-6736(20)30868-0
- 237 8. Hematian A, Sadeghifard N, Mohebi R, et al. Traditional and Modern Cell Culture in Virus Diagnosis.  
238 *Osong public health and research perspectives* 2016;7(2):77-82. doi: 10.1016/j.phrp.2015.11.011  
239 [published Online First: 2016/01/08]


Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

- 240 9. Whiting PF, Rutjes Aw Fau - Westwood ME, Westwood Me Fau - Mallett S, et al. QUADAS-2: a revised  
241 tool for the quality assessment of diagnostic accuracy studies. (1539-3704 (Electronic))  
242 10. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-  
243 analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4(1):1-1. doi: 10.1186/2046-4053-4-1  
244 11. Jeong HW, Kim S-M, Kim H-S, et al. Viable SARS-CoV-2 in various specimens from COVID-19 patients.  
245 *Clin Microbiol Infect* 2020:S1198-743X(20)30427-4. doi: 10.1016/j.cmi.2020.07.020  
246 12. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. (1538-  
247 3598 (Electronic))  
248 13. Xiao F SJ, Xu Y, Li F et al. Infectious SARS-CoV-2 in feces of patient with severe COVID-19. 2020 doi:  
249 <https://doi.org/10.3201/eid2608.200681>  
250 14. Yong Z, Cao C, Shuangli Z, et al. Isolation of 2019-nCoV from a Stool Specimen of a Laboratory-  
251 Confirmed Case of the Coronavirus Disease 2019 (COVID-19). *China CDC Weekly* 2020;2(8):123-24.  
252 doi: 10.46234/ccdcw2020.033  
253 15. Xiao F, Tang M, Zheng X, et al. Evidence for Gastrointestinal Infection of SARS-CoV-2. (1528-0012  
254 (Electronic))  
255 16. Lamers MA-O, Beumer JA-O, van der Vaart JA-O, et al. SARS-CoV-2 productively infects human gut  
256 enterocytes. (1095-9203 (Electronic))  
257 17. Qian Q, Fan L, Liu W, et al. Direct evidence of active SARS-CoV-2 replication in the intestine. *Clinical*  
258 *Infectious Diseases* 2020 doi: 10.1093/cid/ciaa925  
259 18. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a  
260 Skilled Nursing Facility. *New England Journal of Medicine* 2020;382(22):2081-90. doi:  
261 10.1056/NEJMoa2008457  
262 19. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management  
263 tool for discharge of SARS-CoV-2 patients from infectious disease wards. *European Journal of*  
264 *Clinical Microbiology & Infectious Diseases* 2020;39(6):1059-61. doi: 10.1007/s10096-020-03913-9  
265 20. Santarpia JL, Rivera DN, Herrera V, et al. Aerosol and Surface Transmission Potential of SARS-CoV-2.  
266 *medRxiv* 2020:2020.03.23.20039446. doi: 10.1101/2020.03.23.20039446  
267 21. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-  
268 2019. *Nature* 2020;581(7809):465-69. doi: 10.1038/s41586-020-2196-x  
269 22. Kujawski SA, Wong KK, Collins JP, et al. Clinical and virologic characteristics of the first 12 patients with  
270 coronavirus disease 2019 (COVID-19) in the United States. *Nature Medicine* 2020;26(6):861-68. doi:  
271 10.1038/s41591-020-0877-5  
272 23. Yao H, Lu X, Chen Q, et al. Patient-derived mutations impact pathogenicity of SARS-CoV-2. *medRxiv*  
273 2020:2020.04.14.20060160. doi: 10.1101/2020.04.14.20060160  
274 24. Yuan CA-O, Zhu H, Yang YA-OX, et al. Viral loads in throat and anal swabs in children infected with SARS-  
275 CoV-2. (2222-1751 (Electronic))  
276 25. Tom MR, Mina MJ. To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value. *Clinical*  
277 *Infectious Diseases* 2020 doi: 10.1093/cid/ciaa619  
278 26. Hodinka RL. Point: is the era of viral culture over in the clinical microbiology laboratory? *J Clin Microbiol*  
279 2013;51(1):2-4. doi: 10.1128/JCM.02593-12 [published Online First: 2012/10/10]  
280 27. Laboratory support for COVID-19 in the EU/EEA. Testing for SARS-CoV-2 virus European Centre for  
281 Disease Prevention and Control. 2020  
282 28. Cevik M, Tate M, Lloyd O, et al. SARS-CoV-2, SARS-CoV-1 and MERS-CoV viral load dynamics, duration of  
283 viral shedding and infectiousness: a living systematic review and meta-analysis. *medRxiv*  
284 2020:2020.07.25.20162107. doi: 10.1101/2020.07.25.20162107  
285 29. Jansen RR, Wieringa J, Koekkoek SM, et al. Frequent Detection of Respiratory Viruses without  
286 Symptoms: Toward Defining Clinically Relevant Cutoff Values. *J Clin Microbiol* 2011;49(7):2631-36.  
287 doi: 10.1128/jcm.02094-10

288

289  
290  
291

**Figure 1 - PRISMA 2009 Flow Diagram**



Viral cultures for COVID-19 infectivity assessment – a systematic review  
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

Study	Samples (source)	Samples (n) [SST]	Culture methods	Culture Positive	Additional notes
<a href="#">Bullard</a> <sup>4</sup>	Nasopharyngeal (NP) or endotracheal (ETT) from COVID-19 patients (mean age 45 years)	90 [0-7 days]	NP swabs and ETT specimens in viral transport media were stored at 4°C for 24-72 hours until they were tested for the presence of SARS-CoV-2 RNA using real-time RT-PCR targeting a 122nt portion of the Sarbecovirus envelope gene (E gene). Dilutions were placed onto the Vero cells in triplicate and incubated at 37°C with 5% CO2 for 96 hours. Following incubation of 4 days, cytopathic effect was evaluated under a microscope and recorded.	26	The range of symptoms onset to negative PCT was 21 days. Within this period, positive cultures were only observed up to day 8 post symptom onset
<a href="#">Huang</a> <sup>5</sup>	Oropharyngeal (OP) or nasopharyngeal (NP) swabs, or sputum (SP)	60 specimens from 50 cases [3,4 days mean but see table 1 for freeze thaw cycles delays]	SARS-CoV-2 cDNA was prepared using RNA extracted from the specimens of the first patient with confirmed COVID-19. RT was performed using the MMLV Reverse transcription kit. All procedures for viral culture were conducted in a biosafety level-3 facility. Vero-E6 and MK-2 (ATCC) cells were maintained in a virus culture medium and the cells were maintained in a 37°C incubator with daily observations of the cytopathic effect.	12 OP, 9 NP and two from SP specimens were culturable	Specimens with high copy numbers of the viral genome, indicative of higher viral load, were more likely to be culturable
<a href="#">Jeong</a> <sup>11</sup>	Naso/oropharyngeal swabs, saliva, urine, and stool	5 patients	Specimens positive by qPCR were subjected to virus isolation in Vero cells. Urine and stool samples were inoculated intranasally in ferrets and they evaluated the virus titers in nasal washes on 2, 4, 6, and 8 days post-infection (dpi). Immunofluorescence antibody assays were also done.	Naso/ oropharyngeal saliva, urine and stool Samples were collected between days 8 to 30 of the clinical course. Viable SARS-CoV-2 was isolated from 1 naso /	Viral loads in urine, saliva, and stool samples were almost equal to or higher than those in naso / oropharyngeal swabs. After symptom resolution, patients shed viable virus in their saliva and urine up to day 15 of illness



Viral cultures for COVID-19 infectivity assessment – a systematic review  
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

				<p>oropharyngeal swab.                  Ferrets inoculated with patient urine or stool were infected. SARS-CoV-2 was isolated from the nasal washes of the 2 urine-treated ferrets and one stool-treated ferret</p>	
<a href="#">Qian</a> <sup>17</sup>	Rectal tissue obtained from a surgical procedure was available.	1 [1-3 days post op]	Ultrathin sections of tissue fixed in epoxy resin on formvar-coated copper grids were observed under electron microscope under 200kV. Immunohistochemical staining was used to establish expression and distribution of SARS-CoV-2 antigen.	1	No culture done. Visualisation of virions in rectal tissue and detection of SARS-CoV-2 antigen in the rectal tissue.
<a href="#">Wang</a> <sup>12</sup>	Bronchoalveolar fluid, sputum, feces, blood, and urine specimens from hospital inpatients with COVID-19	4 fecal samples with sufficiently high copy numbers from 1070 specimens collected from 205 patients with COVID-19 (mean age of 44 years and 68% male [1-3 days from hospital admission])	rRT-PCR targeting the open reading frame 1ab gene of SARS-CoV-2; cycle threshold values of rRT-PCR were used as indicators of the copy number of SARS-CoV-2 RNA in specimens with lower cycle threshold values corresponding to higher viral copy numbers. A cycle threshold value less than 40 was interpreted as positive for SARS-CoV-2 RNA. Four SARS-CoV-2 positive fecal specimens with high copy numbers were cultured, and then electron microscopy was performed to detect live virus.	4 viewed by electron microscope	The details of how the 4 samples were cultured were not reported. The patients did not have diarrhoea.
<a href="#">Xiao F, Sun J</a> <sup>13</sup>	Serial feces samples collected from 28 hospitalised COVID-19 patients: 3 samples from 3 RNA-positive	3, one patient admitted day 7 post onset	Inoculation of Vero 6 cells. Cycle threshold values for the fecal sample were 23.34 for the open reading frame 1lab gene and 20.82 for the nucleoprotein gene. A cytopathic effect was visible in Vero E cells 2 days after a second-round	2/3 (infectious virus was present in faeces from two cases)	Selection of samples is not entirely clear.

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

	patients were tested for possible viral culture.		passage. The researchers negatively stained culture supernatant and visualized by transmission electron microscopy. Viral particles that were visible were spherical and had distinct surface spike protein projections, consistent with a previously published SARS-CoV2 image.		
<a href="#">Arons</a> <sup>18</sup>	nasopharyngeal and oropharyngeal swabs	46 rRT-PCR–positive specimens [For asymptomatic median 4 days, Ct 23.1]	All rRT-PCR positive samples shipped to USA CDC for viral culture using Vero-CCL-81 cells. Cells showing cytopathic effects were used for SARS-CoV-2 rRT-PCR to confirm isolation and viral growth in culture.	31 [no relation to symptoms presence. Culturable virus isolated from 6 days before to 9 days after symptom onset]	
<a href="#">La Scola</a> <sup>19</sup>	Naso pharyngeal swabs or sputum samples	183 (4384 samples from 3466 patients) [not reported]	From 1049 samples, 611 SARS-CoV-2 isolates were cultured. 183 samples testing positive by RT-PCR (9 sputum samples and 174 nasopharyngeal swabs) from 155 patients, were inoculated in cell cultures. SARS-CoV-2. RNA rtPCR targeted the E gene. Nasopharyngeal swab fluid or sputum sample were filtered and then inoculated in Vero E6 Cells. All samples were inoculated between 4 and 10 h after sampling and kept at + 4 °C before processing. After centrifugation they were incubated at 37 °C. They were observed daily for evidence of cytopathogenic effect. Two subcultures were performed weekly and scanned by electron microscope and then confirmed by specific RT-PCR targeting E gene	Of the 183 samples inoculated in the studied period of time, 129 led to virus isolation. Of these 124 samples had detectable cytopathic effect between 24 and 96 h	There was a significant relationship between Ct value and culture positivity rate: samples with Ct values of 13–17 all had positive culture. Culture positivity rate decreased progressively according to Ct values to 12% at 33 Ct. No culture was obtained from samples with Ct > 34. The 5 additional isolates obtained after blind subcultures had Ct between 27 and 34, thus consistent with low viable virus load.
<a href="#">Santarpia</a> <sup>20</sup>	Windowsill and air, mean 7.3 samples per room. The	13 patients [5-9 of admission but provenance was	Vero E6 cells were used to culture virus from environmental samples. The cells were cultured in Dulbeccos's minimal	Possibly 2 with weak cytopathic effect	Isolates were from days 5 and 8 of occupancy of hospital/isolation rooms

Viral cultures for COVID-19 infectivity assessment – a systematic review  
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

	percentage of PCR positive samples from each room was 40% -100%	Diamond Princess no info on day of symptom kick off]	essential medium (DMEM) supplemented with heat inactivated fetal bovine serum (10%), Penicillin/Streptomycin (10,000 IU/mL & 10,000 µg/mL) and Amphotericin B (25 µg/mL).		
<a href="#">Wölfel</a> <sup>21</sup>	Saliva, nasal swabs, urine, blood and stool	9 patients [2-4 days]		Yes in respiratory samples and indicative in stool	
<a href="#">Kujawski</a> <sup>22</sup> (for The COVID-19 Investigation Team)	Nasopharyngeal (NP), oropharyngeal (OP), stool, serum and urine specimens	9 from 9 patients	SARS-CoV-2 real-time PCR with reverse transcription (rRT-PCR) cycle threshold (Ct) values of virus isolated from the first tissue culture passage were 12.3 to 35.7 and for one patient, virus isolated from tissue culture passage 3 had a titer of $7.75 \times 10^6$ median tissue culture infectious dose per ml; these data were likely more reflective of growth in tissue culture than patient viral load.	9 (including two non hospitalised)	Viable SARS-CoV-2 was cultured at day 9 of illness (patient 10), but was not attempted on later specimens. SARS-CoV-2 rRT-PCR Ct values of virus isolated from the first tissue culture passage were 12.3 to 35.7. Mean Ct values in positive specimens were 17.0 to 39.0 for NP, 22.3 to 39.7 for OP and 24.1 to 39.4 for stool. All blood and urine isolates were negative. Ct values of upper respiratory tract specimens were lower in the first week of illness than the second in most patients, low Ct values continued into the second and third week of illness.
<a href="#">Zhang</a> <sup>14</sup>	Stool	Unknown [not reported]	Vero cells were used for viral isolation from stool samples of COVID-19 patients sent by Heilongjiang CDC. A 2019-nCoV	1	We do not know what influenced successful virus culture e.g. methods

Viral cultures for COVID-19 infectivity assessment – a systematic review  
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

			<p>strain was isolated from a stool specimen of a laboratory-confirmed COVID-19 severe pneumonia case, who experienced onset on January 16, 2020 and was sampled on February 1, 2020. The interval between sampling and onset was 15 days. The full-length genome sequence indicated that the virus had high-nucleotide similarity (99.98%) to that of the first isolated novel coronavirus isolated from Wuhan, China.... In the Vero cells, viral particles with typical morphology of a coronavirus could be observed under the electron microscope</p>		<p>optimal, or concentration of virus optimal. More information needed.</p>
<p><a href="#">Xiao F,</a> <a href="#">Tang M</a><sup>15</sup></p>	<p>Esophageal, gastric, duodenal, and rectal tissues were obtained from 1 COVID-19 patients by endoscopy.</p>	<p>1 plus an unknown additional number of fecal samples from RNA-positive patients. [not reported]</p>	<p>Histological staining (H&amp;E) as well as viral receptor ACE2 and viral nucleocapsid staining were performed.</p>	<p>1/1 RNA-positive patient. Positive staining of viral nucleocapsid protein was visualized in the cytoplasm of gastric, duodenal, and rectum glandular epithelial cell, but not in esophageal epithelium of the 1 patient providing these tissues. Additionally, positive staining of ACE2 and SARS-CoV-2 was also observed in gastrointestinal epithelium from other patients who tested positive for SARS-CoV-2 RNA in feces, results not</p>	<p>Total sample numbers are not reported.</p>

Viral cultures for COVID-19 infectivity assessment – a systematic review  
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

				shown.	
Yao <sup>23</sup>	Sputum (n=7), stool (n=3) and one nasopharyngeal sample	11 patients admitted to hospital 9 classified as serious or critical, 1 moderate, 1 mild symptoms [0-16 days]	<p>The samples of the 11 patients involved in this study were collected during the early phase of the COVID-19 break out in China, dates ranging from 2nd of January to the 2nd of April 2020.</p> <p>All except one of the patients had moderate or worse symptoms. Three patients had co-morbidities and one patient needed ICU treatment. Seven patients had sputum samples, one nasopharyngeal and three had stool samples</p> <p>The samples were pre-processed by mixing with appropriate volume of MEM medium with 2% FBS, Amphotericin B, Penicillin G, Streptomycin , and TPCK-trypsin. The supernatant was collected after centrifugation at 3000 rpm at room 434 temperature. Before infecting Vero-E6 cells, all collected supernatant was filtered using a 435 0.45 µm filter to remove cell debris etc.</p> <p>Vero-E6 cells were infected with 11 viral isolates and quantitatively assessed their viral load at 1, 2, 4, 8, 24, and 48 hours post-infection (PI) and their viral cytopathic effects (CPE) at 48 and 72 hours PI. and examined whether the viral isolates could successfully bind to Vero-E6 243 cells as expected. Super-deep sequencing of the 11 viral isolates on the Novaseq 6000 platform was performed</p>	11 samples taken up to 16 days from admission to hospital.	<p>Cultured viruses were inoculated in Vero cells. At 8 hours post-infection there was a significant decrease in Ct value (increases in viral load) for five isolates. At 24 hours significant decreases in the Ct values for all of the viral isolates were observed.</p> <p>Mutations of the viruses are also reported</p>

Table 1. Characteristics of included studies. Key: STT = symptom onset to test date

Viral cultures for COVID-19 infectivity assessment – a systematic review  
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

Study	Description of methods and sufficient detail to replicate	Sample sources clear	Analysis & reporting appropriate	Is bias dealt with	Applicability
Bullard 2020 <sup>4</sup>	Yes	yes	yes	unclear	unclear
Santarpia 2020 <sup>20</sup>	Yes	yes	yes	unclear	unclear
Wölfel 2020 <sup>21</sup>	Yes	yes	yes	unclear	unclear
Huang 2020 <sup>5</sup>	yes	yes	yes	unclear	unclear
Wang W <sup>12</sup> 2020	No	yes	yes	no	unclear
Zhang Y 2020 <sup>14</sup>	Partly	yes	yes	no	unclear
Xiao 2020b <sup>15</sup>	No	yes	yes	no	unclear
Qian Q 2020 <sup>17</sup>	Yes	yes	yes	unclear	unclear
Arons 2020 <sup>18</sup>	Yes	yes	yes	yes	unclear
Xiao F 2020 <sup>13</sup>	Yes	yes	yes	no	unclear
Kujawski 2020 <sup>22</sup>	Yes	yes	yes	unclear	unclear
Jeong 2020 <sup>11</sup>	Yes	yes	yes	no	unclear
La Scola 2020 <sup>19</sup>	Yes	yes	yes	unclear	unclear
Yoa H 2020 <sup>23</sup>	Yes	yes	yes	unclear	unclear

Table 2. Quality of included studies